Drug Information

Drug General Information
Drug ID
D0X4ZV
Former ID
DIB007010
Drug Name
BAX-499
Synonyms
ARC-19499; Tissue factor pathway inhibitor (hemophilia A/hemophilia B), Archemix
Indication Factor IX deficiency [ICD10:D67] Phase 1 [523151]
Company
Archemix Corp
Target and Pathway
Target(s) Tissue factor pathway inhibitor Target Info Inhibitor [531922], [532285]
KEGG Pathway Complement and coagulation cascades
NetPath Pathway IL4 Signaling Pathway
TGF_beta_Receptor Signaling Pathway
PANTHER Pathway Blood coagulation
Pathway Interaction Database Syndecan-4-mediated signaling events
Reactome Extrinsic Pathway of Fibrin Clot Formation
WikiPathways Complement and Coagulation Cascades
Integrated Breast Cancer Pathway
Formation of Fibrin Clot (Clotting Cascade)
References
Ref 523151ClinicalTrials.gov (NCT01191372) First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients. U.S. National Institutes of Health.
Ref 531922Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma. J Thromb Haemost. 2012 Aug;10(8):1581-90.
Ref 532285Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction with multiple domains of the protein. J Thromb Haemost. 2013 Jun;11(6):1137-45.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.